Estrogen and Progesterone Receptors Expression in Uterine Malignant Smooth Muscle Tumors: Correlation with Clinical Outcome

Journal of Chemotherapy

Volumn 15, Issue 6, 2003, Pages 596-602

  Raspollini, M R ^a   Amunni, G ^a   Villanucci, A ^a   Boddi, V ^a   Simoni, A ^a   Taddei, A ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clinical outcome; Estrogen receptor; Progesterone receptor; Prognosis; Uterine leiomyosarcoma

Indexed keywords

CISPLATIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; IFOSFAMIDE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CALCULATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; MODEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 1242317733     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.6.596     Document Type: Article

References (43)

1. Silverberg SG. Leiomyosarcoma of the uterus. A clinicopathologic study. Obstet Gynecol 1971; 38: 613-628.
2. Wilkinson N, Rollason TP. Recent advances in the pathology of smooth muscle tumours of the uterus. Histopathology. 2001; 39: 331-341.
3. Clement PB. The pathology of uterine smooth muscle tumors and mixed endometrial stroma-smooth muscle tumors: a selective review with emphasis on recent advances. Int J Gynecol Pathol 2000; 19: 39-55.
4. Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988; 62: 2239-2247.
5. Kempson RL, Hendricks. Pure mesenchymal neoplasm of the uterine corpus. In: H. Fox, ed. Haines and Taylor obstetrical and gynaecological pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1987: 411-456.
6. Zaloudek CJ, Norris HJ. Mesenchymal tumors of the uterus. In: RJ Kurman (ed.) Blausteins' pathology of the female genital tract (3th ed.), Springer, New York 1987: 373-408.
7. Nola M, Babic D, Ilic J, et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996; 78: 2543-2550.
8. Chang LK, Crabtree GS, Lim-Tan SK, et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 1990; 14: 415-438.
9. Silverberg SG. Reproducibility of the mitosis count in the histologic of smooth muscle tumours of the uterus. Hum Pathol 1976; 7: 451-454.
10. Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early stage uterine sarcoma. Cancer 1993; 71: 1702-1709.
11. Silverberg SG. Reproducibility of the mitosis count in the histologic of smooth muscle tumours of the uterus. Hum Pathol. 1976; 7: 451-454.
12. Ellis PSJ, Whitehead R. Mitosis counting: a need for reappraisal. Hum Pathol. 1981; 12: 3-4.
13. Jeffers MD, Oakes SJ, Richmond JA, Macaulay EM. Proliferation, ploidy and prognosis in uterine smooth muscle tumours. Histopathology. 1996; 29: 217-223.
14. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. Am J Surg Pathol. 1994; 18: 535-558.
15. Jones MW, Norris HJ. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol. 1995; 14: 243-249.
16. th edition. New York: Springer-Verlag, 1994: 487-528.
17. Ali S, Wells M. Mixed mullerian tumors of the uterine corpus: a review. Int J Gynecol Cancer. 1993; 3: 1-11.
18. Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993; 71: 1702-1709.
19. Nola M, Babic D, Ilic J, et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996; 78: 2543-2550.
20. Mayerhofer K, Obermairn A, Windbichler G, Petru E, Kaiser A, Hefler L et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999; 74: 196-201.
21. th ed./editor, Robert J Kurmann. Spriner-Verlag New York Berlin Heidelberg.
22. TNM Classification of malignant tumours. UICC. Sobin LH and Wittekind Ch Editors. Geneva, Switzerland. Sixty ed. 2002.
23. Mayerhofer K, Obermairn A, Windbichler G, Petru E, Kaiser A, Hefler L et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999; 74: 196-201.
24. Li S, Shiozawa T, Nakayama K, Nikaido T, Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and Cyclin E in uterine endometrioid carcinoma. Cancer. 1996; 77: 321-327.
25. Zhai YA, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, Fujii S. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999; 18: 20-28.
26. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and Progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 2003; 23: 729-732.
27. Stata Press: Statistics-Stata 7. Reference Q-ST. 4905 Lakeway Drive, College Station, Texas 77845, 2000.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
29. Osborne CK, Yochmowitz MG, Knight WA et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46: 2884-2888.
30. Enrlich CE, Young PCM, Cleary RE. Cytoplasmatic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications Am J Obstet Gynecol. 1981; 141: 539-546.
31. Brandis A, Mirzai S, Tabagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex ormone receptor in meningiomas: correlation with clinical and histological features. Neurosurgery. 1993; 33: 212-218.
32. Kawaguchi K, Fujii S, Konishi I et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Vircow Arch A Pathol Anat 1991; 419: 309-315.
33. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptors messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993; 169: 78-85.
34. Zhai YA, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, Fujii S. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999; 18: 20-28.
35. Kanetoshi K, Shingo F, Ikuo K et al. Immunohistochemical analysis of estrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchow Archiv A Pathol Anat 1991, 419: 309-315.
36. Filicori M, Hall DA, Loughlin J et al. A conservative approach to the management of uterine leiomyomata: pituitary desensitisation by luteinising hormone releasing hormone analogue. Am J Obstet Gynecol 1983; 147: 726-727.
37. West CP, Lumsden MA, Lawson S, Williamson J, Baird DT. Shrinkage of uterine fibroids during therapy with Zoladex (ICI 118630): a luteinising hormone releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45-51.
38. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. I J Gynecol Pathol 1985; 4: 89-96.
39. Wu X, Blanck A, Olovsson M, Moller B, Favini R, Lindblom B. Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. Acta Obstet Gynecol Scand 2000; 79: 397-404.
40. Soper JT, McCarty KS, Hinshaw W et al. Citoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 1984; 150: 342-348.
41. Sutton GP, Stehman FB, Michael H et al. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 1986; 68: 709-714.
42. Mittal K, Demopoulos RI. MIB1 (Ki-67), p53, estrogen, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001; 32: 984-987.
43. Zhai Y-L, Kobayashi Y, Mori A et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999; 18: 20-28.